Drug resistance in the treatment of sarcomas.
Drug resistance in the treatment of sarcomas.
复制标题
肉瘤治疗中的耐药性。
DOI：
--
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
Colvin Om
中科院分区：
文献类型：
--
作者：
Colvin Om
本文综述了近年来用于治疗肉瘤的化疗药物的作用和耐药性的发展，包括烷化剂（环磷酰胺、异环磷酰胺、达卡巴嗪）、铂类化合物（顺铂、卡铂）、蒽环类化合物阿霉素、拓扑异构酶II抑制剂依托泊苷和紫杉烷类（紫杉醇、泰索帝）。讨论的耐药机制包括细胞内谷胱甘肽和金属蛋白酶水平的变化、醛脱氢酶水平升高、DNA修复增强和细胞凋亡保护（对于烷化剂）; 0-6烷基转移酶水平升高（对于达卡巴嗪）;多药耐药1-和多药耐药相关蛋白介导的细胞药物输出（蒽环类、紫杉烷类）;以及微管结构改变（紫杉烷类）。
The antineoplastic action and development of drug resistance are reviewed for chemotherapeutic agents used in the treatment of sarcoma, including alkylating agents (cyclophosphamide, ifosphamide, dacarbazine), platinum compounds (cisplatin, carboplatin), the anthracycline compound doxorubicin, the topoisomerase II inhibitor etoposide, and the taxanes (paclitaxel, taxotere). Drug resistance mechanisms discussed include changes in intracellular glutathione and metallothione levels, increased aldehyde dehydrogenase levels, enhanced DNA repair and protection from apoptosis (for alkylating agents); increased 0-6 alkyltranferase levels (for dacarbazine); multidrug resistance 1- and multidrug resistance associated protein-mediated drug export from cells (anthracyclines, taxanes); and structural alteration of microtubules (taxanes).